Startups channel feed

Psy­che­del­ic-as­sist­ed drug de­vel­op­er MAPS PBC nabs $100M, re­names to Lykos Ther­a­peu­tics

Last year
Financing

Feng Zhang's CRISPR start­up Aera shrinks head­count by a quar­ter

Last year
People

Claris rais­es $57M in Se­ries A as it awaits key tri­al read­out on eye drug

Last year
Financing
R&D

Ex­clu­sive: Roger Perl­mut­ter on the biggest prob­lem in Big Phar­ma, leav­ing Mer­ck, and build­ing Eikon

Last year
People
R&D

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Last year
Financing
China

Backed by CRISPR pi­o­neer Feng Zhang, epi­ge­net­ics biotech Moon­walk de­buts with $57M

Last year
Cell/Gene Tx

Roche pens third pact of the week in $66M up­front to MO­MA Ther­a­peu­tics

Last year
Deals
Pharma

Ex­clu­sive: Af­ter Turn­ing Point suc­cess, on­col­o­gy vets in-li­cense first as­set for Aven­zo Ther­a­peu­tics

Last year
Deals
China

No­vo’s broad Flag­ship part­ner­ship starts with obe­si­ty at Omega and MASH at Cel­lar­i­ty

Last year
Deals
Pharma

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Last year
R&D
In Focus

Gold­man Sachs clos­es $650M life sci­ences fund to bankroll in­dus­try’s ‘gold­en era’

Last year
Financing

Roche lines up RNA pact with Remix Ther­a­peu­tics, which al­so raised an­oth­er $60M

Last year
Financing
Deals

Shunned by in­sur­ers, dig­i­tal ther­a­peu­tics star­tups look for oth­er ways to get paid

Last year
Health Tech

Ex­clu­sive: Health­care start­up De­vot­ed Health rais­es $175M

Last year
Health Tech

Lil­ly part­ners with start­up Fau­na Bio to see if a squir­rel’s hi­ber­na­tion could lead to new obe­si­ty drugs

Last year
Deals
Pharma

Ex­clu­sive: Su­do Bio­sciences se­cures $116M to start tri­als of its oral and top­i­cal TYK2 can­di­dates

Last year
Financing

Lassen Ther­a­peu­tics reels in $85M Se­ries B for PhII test­ing in thy­roid eye dis­ease

Last year
Financing

Ex­clu­sive: Kimia Ther­a­peu­tics se­cures $55M to su­per­charge co-founder’s plat­form, cre­ate ‘next-gen­er­a­tion Car­mot’

Last year
Financing

To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Last year
Financing

Play­ground rais­es $410M fund, Ar­tis clos­es $200M as bi­ol­o­gy and tech VC con­ver­gence con­tin­ues

Last year
Financing

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Last year
Financing
AI

MIT gene edit­ing spin­out launch­es with $213M to write the 'fi­nal chap­ter in ge­nom­ic med­i­cine'

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: Shi­no­bi rais­es $51M to take on cell ther­a­py chal­lenges with ex-Wu­gen CEO at helm, Carl June in sup­port

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: Women’s health biotech Freya Bio­sciences rais­es $38M for mi­cro­bial im­munother­a­pies

Last year
Financing
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times